Glenmark Licenses Cancer Drug Envafolimab for Asia & More
January 25, 2024 10:54
Glenmark Pharmaceuticals has secured licensing rights for Envafolimab, a cancer drug, in India, Asia Pacific, and other regions. The drug, developed by Jiangsu Alphamab and 3D Medicines, is a PD-L1...